Edition:
United States

AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

5,027.00GBp
28 Jul 2016
Change (% chg)

-- (--)
Prev Close
5,027.00p
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,696,691
52-wk High
5,052.00p
52-wk Low
3,680.00p

AZN.L

Chart for AZN.L

About

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease... (more)

Overall

Beta: 0.66
Market Cap(Mil.): £58,893.18
Shares Outstanding(Mil.): 1,264.62
Dividend: 131.00
Yield (%): 4.02

Financials

  AZN.L Industry Sector
P/E (TTM): 26.66 35.76 36.62
EPS (TTM): 1.75 -- --
ROI: 6.87 15.33 14.52
ROE: 18.44 16.37 15.68

UPDATE 2-AstraZeneca a bid target again? CEO says someone may spot value

* Novartis stock down 1.8 percent (Adds latest AstraZeneca and Novartis shares)

Jul 28 2016

AstraZeneca earnings hit by waning cholesterol drug sales

LONDON, July 28 Generic competition to cholesterol fighter Crestor in the key U.S. market hit second-quarter earnings at drugmaker AstraZeneca, which is now banking on new cancer medicines to revive its fortunes.

Jul 28 2016

BRIEF-Astrazeneca and Moderna files first clinical trial application in RNA therapeutics

* Astrazeneca and Moderna announce filing of first clinical trial application in messenger RNA therapeutics(tm) collaboration

Jul 26 2016

AstraZeneca's lung cancer drug meets main goal in late-stage trial

AstraZeneca Plc said its experimental lung cancer drug Tagrisso met its main goal in a late-stage study.

Jul 18 2016

BRIEF-Astrazeneca's lung cancer drug meets primary endpoint in late-stage trial

* Objective response rate, disease control rate, duration of response achieved clinically meaningful improvement versus chemotherapy

Jul 18 2016

UPDATE 1-AstraZeneca's lung cancer drug meets main goal in late-stage trial

July 18 AstraZeneca Plc said its experimental lung cancer drug Tagrisso met its main goal in a late-stage study.

Jul 18 2016

AstraZeneca's lung cancer drug meets main goal in late-stage trial

July 18 AstraZeneca Plc said its experimental lung cancer drug Tagrisso met its primary endpoint in a late-stage study.

Jul 18 2016

AstraZeneca resolves Faslodex patent litigation in U.S.

British drugmaker AstraZeneca Plc said on Wednesday it has entered into an agreement with Sandoz, the generic pharmaceuticals division of Novartis AG, to resolve Faslodex patent litigation in the U.S.

Jul 13 2016

AstraZeneca resolves Faslodex patent litigation in U.S.

July 13 British drugmaker AstraZeneca Plc said on Wednesday it has entered into an agreement with Sandoz, the generic pharmaceuticals division of Novartis AG , to resolve Faslodex patent litigation in the U.S.

Jul 13 2016

BRIEF-AstraZeneca says Health Canada approves tagrisso for treatment of non-small cell lung cancer

* Tagrisso approved by Health Canada as treatment for patients with locally advanced or metastatic EGFR T790M mutation-positive non-small cell lung cancer Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

Jul 11 2016

Earnings vs. Estimates